Comerica Bank Collegium Pharmaceutical, Inc Transaction History

Comerica Bank

$25 Billion
Q3 2024

A detailed history of Comerica Bank transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Comerica Bank holds 24,849 shares of COLL stock, worth $763,112. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,849

Previous 24,010 3.49%

Holding current value

$763,112

Previous $773,000 24.19%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$31.4 - $39.07 $26,344 - $32,779	839 Added 3.49%	24,849 $960,000
Q2 2024 Aug 15, 2024	SELL	$31.36 - $39.99 $33,617 - $42,869	-1,072 Reduced 4.27%	24,010 $773,000
Q1 2024 May 15, 2024	BUY	$31.23 - $40.91 $301,275 - $394,658	9,647 Added 62.5%	25,082 $973,000
Q4 2023 Feb 14, 2024	SELL	$21.16 - $30.8 $14,092 - $20,512	-666 Reduced 4.14%	15,435 $475,000
Q3 2023 Nov 21, 2023	BUY	$21.23 - $24.28 $341,824 - $390,932	16,101 New	16,101 $359,000
Q4 2022 Jan 26, 2023	SELL	$16.14 - $23.55 $100,536 - $146,692	-6,229 Reduced 23.78%	19,965 $0
Q3 2022 Oct 28, 2022	SELL	$15.46 - $20.1 $50,786 - $66,028	-3,285 Reduced 11.14%	26,194 $461,000
Q1 2022 Apr 27, 2022	SELL	$17.2 - $22.5 $4,730 - $6,187	-275 Reduced 0.92%	29,479 $600,000
Q4 2021 Feb 18, 2022	SELL	$17.5 - $21.35 $45,132 - $55,061	-2,579 Reduced 7.98%	29,754 $555,000
Q3 2021 Nov 22, 2021	SELL	$17.75 - $25.39 $12,141 - $17,366	-684 Reduced 2.07%	32,333 $638,000
Q2 2021 Aug 26, 2021	SELL	$21.74 - $25.28 $51,175 - $59,509	-2,354 Reduced 6.66%	33,017 $780,000
Q1 2021 Apr 28, 2021	BUY	$19.25 - $26.1 $680,891 - $923,183	35,371 New	35,371 $838,000

Others Institutions Holding COLL

# of Institutions

256

Shares Held

38.6M

Call Options Held

100K

Put Options Held

21.1K

View Full List

About COLLEGIUM PHARMACEUTICAL, INC

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.05B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

More about COLL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Comerica Bank, based on Form 13F filings with the SEC.

News

Stay updated on Comerica Bank with notifications on news.

Account